The SNMMI 2022 International Best Abstract Award for Iran

Abstract submitted by Dr. Hessamoddin Roustaei entitled (In vivo assessment of CXCR4 receptor expression in High-grade Glioma using [Ga-68] Ga-Pentixafor PET/CT (under the brand name of PARS- CixaFor)), received the International Best Abstract Award for Iran at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging 2022 (SNNMI 2022).

Besides thanking his colleagues in Ghaem and Razavi hospitals in Mashhad, Dr. Roustaei thanked Pars Isotope Co. for its efforts in producing and supplying this radiopharmaceutical. Glioblastoma is a type of brain cancer known as the most common malignant brain tumor. This tumor is very invasive and grows and spreads rapidly. Although there is almost no definitive treatment for it, some treatments such as surgery, radiation therapy or chemotherapy can relieve symptoms, slow down and control tumor growth.

Physical examination, blood tests, biopsies, and MRI imaging or CT scans are common methods for diagnosing the disease. However, PET / CT imaging using PARS-Cixafor radiopharmaceutical is a simple, non-invasive and painless diagnostic method that helps doctors to identify the exact location of the tumor in the brain and choose the appropriate treatment approach after diagnosis.